Sands Capital

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.